dvm360 Reports on Gallant’s Platform and Path Toward FDA-Labeled Therapies
July 10, 2025 4:45 AM ET
dvm360 profiled Gallant’s stem cell therapy platform and $18M Series B raise in a July 2025 feature focused on innovation in veterinary medicine.
From dvm360
Veterinary stem cell therapy advances toward FDA approval with $18M in funding
Gallant is redefining veterinary medicine with ready-to-use stem cell therapies that reduce inflammation, restore function, and fit seamlessly into everyday practice.